Age-dependent decline of β-cell function in type 1 diabetes after diagnosis: a multi-centre longitudinal study (Q44916781)

7 December 2017

title

Age-dependent decline of β-cell function in type 1 diabetes after diagnosis: a multi-centre longitudinal study (English)

1 reference

7 December 2017

0 references

5

1 reference

7 December 2017

7

1 reference

7 December 2017

Thomas Mandrup-Poulsen

10

1 reference

7 December 2017

16

1 reference

7 December 2017

N Hosszufalusi

4

0 references

Nicholas J. Wareham

14

object named as

N Wareham

1 reference

7 December 2017

A Barker

1

1 reference

7 December 2017

A Lauria

2

1 reference

7 December 2017

N Schloot

3

1 reference

7 December 2017

C Mathieu

6

1 reference

7 December 2017

M Nordwall

8

1 reference

7 December 2017

B Van der Schueren

9

1 reference

7 December 2017

W A Scherbaum

11

1 reference

7 December 2017

I Weets

12

1 reference

7 December 2017

F K Gorus

13

1 reference

7 December 2017

R D Leslie

15

1 reference

7 December 2017

publication date

29 October 2013

1 reference

Diabetes, Obesity and Metabolism

7 December 2017

published in

1 reference

7 December 2017

volume

16

1 reference

7 December 2017

issue

3

1 reference

7 December 2017

page(s)

262-267

1 reference

C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.

7 December 2017

cites work

1 reference

Challenges in developing endpoints for type 1 diabetes intervention studies

21 January 2018

1 reference

Type 1 diabetes mellitus in 2011: Heterogeneity of T1DM raises questions for therapy

21 January 2018

1 reference

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

21 January 2018

1 reference

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

21 January 2018

1 reference

Correlations between fasting plasma C-peptide, glucagon-stimulated plasma C-peptide, and urinary C-peptide in insulin-treated diabetics.

21 January 2018

1 reference

Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-peptide response to intravenous glucagon

21 January 2018

1 reference

C-peptide Response to Glucagon: A Test for the Residual β-cell Function in Diabetes Mellitus

21 January 2018

1 reference

Correlation between fasting serum C-peptide and B cell insulin secretory capacity in diabetes mellitus.

21 January 2018

1 reference

Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data

21 January 2018

1 reference

Clinical evolution of beta cell function in youth with diabetes: the SEARCH for Diabetes in Youth study

21 January 2018

1 reference

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes

21 January 2018

1 reference

Age-corrected beta cell mass following onset of type 1 diabetes mellitus correlates with plasma C-peptide in humans

21 January 2018

1 reference

Multinational study in children and adolescents with newly diagnosed type 1 diabetes: association of age, ketoacidosis, HLA status, and autoantibodies on residual beta-cell function and glycemic control 12 months after diagnosis

21 January 2018

1 reference

Parameters associated with residual insulin secretion during the first year of disease in children and adolescents with Type 1 diabetes mellitus

21 January 2018

1 reference

Genetic analysis of adult-onset autoimmune diabetes

21 January 2018

1 reference

Insulin autoantibodies and high titre islet cell antibodies are preferentially associated with the HLA DQA1*0301-DQB1*0302 haplotype at clinical type 1 (insulin-dependent) diabetes mellitus before age 10 years, but not at onset between age 10 and 40

21 January 2018

1 reference

Genetic and immunological findings in patients with newly diagnosed insulin-dependent diabetes mellitus. The Swedish Childhood Diabetes Study Group and The Diabetes Incidence in Sweden Study (DISS) Group

21 January 2018

1 reference

Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans

21 January 2018

1 reference

Sex differences in autoimmune disease from a pathological perspective

21 January 2018

1 reference

Autoimmune polyglandular syndrome. II: Clinical syndrome and treatment

21 January 2018

1 reference

GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.

21 January 2018

1 reference

The epidemiology of Type 1 diabetes mellitus is not the same in young adults as in children.

21 January 2018

1 reference

Epidemiology, clinical aspects, and biology of IDDM patients under age 40 years. Comparison of data from Antwerp with complete ascertainment with data from Belgium with 40% ascertainment. The Belgian Diabetes Registry

21 January 2018

1 reference

Sex- and season-dependent differences in C-peptide levels at diagnosis of immune-mediated type 1 diabetes

21 January 2018

1 reference

Residual beta cell function at diagnosis of type 1 diabetes in children and adolescents varies with gender and season.

21 January 2018

1 reference

Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients

21 January 2018

1 reference

C-peptide is a bioactive peptide

21 January 2018

1 reference

C-peptide an adequate endpoint in type 1 diabetes

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12216

1 reference

7 December 2017

1 reference